Wednesday, April 15

Healthcare

Trials for psychedelic drug candidate for PTSD under scrutiny by FDA – report

08/26/20241 Min Read

candidate drug FDA psychedelic PTSD report scrutiny Trials

Previous ArticleWHO says $135M needed to counter mpox outbreak

Next Article ARCA biopharma approves 1-for-12 reverse stock split